Skip to main content
Premium Trial:

Request an Annual Quote

Drug of Choice

The Wall Street Journal reports that GlaxoSmithKline is seeking direction from healthcare officials in France, Italy, Spain, and the UK on what drugs under development at Glaxo should be pursued. The pharma company hopes that this will give rise to more drugs that the healthcare systems will buy. A blog post from the WSJ highlights this problem: UK health advisors decided that Glaxo's new breast cancer drug, Tyverb (Tykerb in the US), isn't effective enough for to warrant its £20,000 per year price tag.

The Scan

Rise of BA.5

The New York Times reports that the Omicron subvariant BA.5 has become the dominant version of SARS-CoV-2 in the US.

UK Health Secretary Resigns

Sajid Javid, the UK health secretary, resigned along with Chancellor Rishi Sunak, saying they cannot work with Prime Minister Boris Johnson's government, CNN reports.

Clones From Freeze-Dried Cells

A team in Japan has cloned mice from freeze-dried skin cells, according to the Guardian.

Genome Research Papers on Craniosynostosis, Macaque Retrotransposition, More

In Genome Research this week: structural variants in craniosynostosis, LINE-1 activity in rhesus macaque brain, and more.